Cover Image
市場調查報告書

人類乳突病毒E6蛋白:開發中產品分析

Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016

出版商 Global Markets Direct 商品編碼 368720
出版日期 內容資訊 英文 66 Pages
訂單完成後即時交付
價格
Back to Top
人類乳突病毒E6蛋白:開發中產品分析 Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016
出版日期: 2016年07月30日 內容資訊: 英文 66 Pages
簡介

本報告提供以人類乳突病毒E6蛋白為標的治療藥之開發平台現狀及最新更新的各開發階段比較分析,提供您附最新的新聞和發表之企業和研究機關正在開發的治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

人類乳突病毒E6蛋白 概要

治療藥的開發

  • 開發中的產品:各開發階段
  • 開發中的產品:各治療領域
  • 開發中的產品:不同症狀

開發中產品概況

  • 後期階段的產品
  • 初期階段的產品

企業開發中的產品

大學/機關開發中的產品

治療藥的評估

  • 單劑/並用治療藥的情況
  • 各給藥途徑
  • 各分子類型

治療藥的開發企業

  • BioNTech AG
  • Cancer Research Technology Limited
  • Etubics Corporation
  • Genexine, Inc.
  • Inovio Pharmaceuticals, Inc.
  • MedImmune, LLC
  • Selecta Biosciences, Inc.
  • Tomegavax, Inc.
  • Transgene SA

藥物簡介

暫停中的計劃

開發中止的產品

主要消息及新聞稿

附錄

圖表

目錄
Product Code: GMDHC0435TDB

Summary

Global Markets Direct's, 'Human Papillomavirus Protein E6 (E6) - Pipeline Review, H2 2016', provides in depth analysis on Human Papillomavirus Protein E6 (E6) targeted pipeline therapeutics.

The report provides comprehensive information on the Human Papillomavirus Protein E6 (E6), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

  • The report provides a snapshot of the global therapeutic landscape for Human Papillomavirus Protein E6 (E6)
  • The report reviews Human Papillomavirus Protein E6 (E6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Human Papillomavirus Protein E6 (E6) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Human Papillomavirus Protein E6 (E6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Human Papillomavirus Protein E6 (E6) targeted therapeutics

Reasons to buy

  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Human Papillomavirus Protein E6 (E6)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Human Papillomavirus Protein E6 (E6) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Human Papillomavirus Protein E6 (E6) Overview
  • Therapeutics Development
    • Human Papillomavirus Protein E6 (E6) - Products under Development by Stage of Development
    • Human Papillomavirus Protein E6 (E6) - Products under Development by Therapy Area
    • Human Papillomavirus Protein E6 (E6) - Products under Development by Indication
  • Human Papillomavirus Protein E6 (E6) - Pipeline Products Glance
    • Late Stage Products
    • Early Stage Products
  • Human Papillomavirus Protein E6 (E6) - Products under Development by Companies
  • Human Papillomavirus Protein E6 (E6) - Products under Development by Universities/Institutes
  • Human Papillomavirus Protein E6 (E6) - Therapeutics Assessment
    • Assessment by Monotherapy/Combination Products
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Human Papillomavirus Protein E6 (E6) - Companies Involved in Therapeutics Development
    • BioNTech AG
    • Cancer Research Technology Limited
    • Etubics Corporation
    • Genexine, Inc.
    • Inovio Pharmaceuticals, Inc.
    • MedImmune, LLC
    • Selecta Biosciences, Inc.
    • Tomegavax, Inc.
    • Transgene SA
  • Human Papillomavirus Protein E6 (E6) - Drug Profiles
    • Antibodies to Target E6 for HPV Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • ETBX-041 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • GX-188E - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus [serotypes 16] vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • human papillomavirus vaccine - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-3106 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • INO-3112 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PVX-01 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • SEL-701 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Synthetic Peptide to Inhibit HPV E6 Protein for HPV Associated Cancer - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TA-CIN - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • TG-4001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vaccine for Cervical Intraepithelial Neoplasia - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • VGX-3100 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • Vvax-001 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Human Papillomavirus Protein E6 (E6) - Dormant Projects
  • Human Papillomavirus Protein E6 (E6) - Discontinued Products
  • Human Papillomavirus Protein E6 (E6) - Featured News & Press Releases
    • Mar 30, 2016: Inovio Pharmaceuticals HPV Immunotherapy Selected as "Best Therapeutic Vaccine" by World Vaccine Congress
    • Mar 29, 2016: Inovio Updates INO-3112 HPV Immunotherapy Development Plan
    • Nov 05, 2015: Inovio's INO-3112 Shows Robust Immune Responses in Patients With Head & Neck Cancer
    • Sep 17, 2015: Inovio Pharmaceuticals Publishes Successful Phase 2b Trial Results of Its HPV Immunotherapy in The Lancet
    • Jul 23, 2015: Inovio Pharmaceuticals and European Organization for Research and Treatment of Cancer to Collaborate on Large Phase II Cervical Cancer Trial
    • Apr 09, 2015: Inovio Pharmaceuticals' HPV Immunotherapy Recognized as "Best Therapeutic Vaccine" by World Vaccine Congress
    • Apr 09, 2015: Inovio Pharmaceuticals HPV Immunotherapy Activates Robust In Vivo T Cell Responses in Head & Neck Cancer Patients
    • Dec 23, 2014: Selecta and Skolkovo Foundation Collaboration to Develop a Synthetic Vaccine Particle in the field of Immuno-oncology
    • Oct 30, 2014: Genexine's HPV Therapeutic Vaccine Achieved High Efficacy in Phase I Cervical Dysplasia Trial
    • Sep 22, 2014: Inovio Pharmaceuticals Expands HPV Immunotherapy Development to Aerodigestive Cancers
    • Jul 23, 2014: Inovio Pharmaceuticals HPV Immunotherapy Achieves Primary Efficacy Endpoint in Randomized Phase II Cervical Dysplasia Trial
    • Jun 11, 2014: Inovio Pharmaceuticals Clarifies Facts of its VGX-3100 Phase II Trial and Immunotherapy Technology
    • Jun 10, 2014: Inovio Pharmaceuticals Initiates Immune Therapy Trial for Head & Neck Cancer Caused by HPV
    • Jul 01, 2013: Etubics Awarded Grant To Develop HPV Immunotherapy Targeting Head & Neck Cancer
    • Nov 26, 2012: Inovio Pharma's Cytomegalovirus Synthetic Vaccine Generates Strong And Broad T-cell Responses In Preclinical Study
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Late Stage Development, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Number of Products under Development by Companies, H2 2016
  • Products under Development by Companies, H2 2016
  • Number of Products under Investigation by Universities/Institutes, H2 2016
  • Products under Investigation by Universities/Institutes, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Stage and Route of Administration, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
  • Pipeline by BioNTech AG, H2 2016
  • Pipeline by Cancer Research Technology Limited, H2 2016
  • Pipeline by Etubics Corporation, H2 2016
  • Pipeline by Genexine, Inc., H2 2016
  • Pipeline by Inovio Pharmaceuticals, Inc., H2 2016
  • Pipeline by MedImmune, LLC, H2 2016
  • Pipeline by Selecta Biosciences, Inc., H2 2016
  • Pipeline by Tomegavax, Inc., H2 2016
  • Pipeline by Transgene SA, H2 2016
  • Dormant Projects, H2 2016
  • Discontinued Products, H2 2016

List of Figures

  • Number of Products under Development for, H2 2016
  • Number of Products under Development by Therapy Area, H2 2016
  • Number of Products under Development by Indication, H2 2016
  • Comparative Analysis by Early Stage Products, H2 2016
  • Assessment by Monotherapy/Combination Products, H2 2016
  • Number of Products by Routes of Administration, H2 2016
  • Number of Products by Stage and Routes of Administration, H2 2016
  • Number of Products by Molecule Types, H2 2016
  • Number of Products by Stage and Molecule Type, H2 2016
Back to Top